News

Medscape2y
FDA Approves First Oral Agent For Anemia in Kidney Dialysis Patients
The US Food and Drug Administration (FDA) has approved daprodustat (Jesduvroq), the first oral treatment for anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for ...
The American Journal of Managed Care2y
FDA Approves Daprodustat for Anemia From CKD in Adult Dialysis Patients
Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States. The FDA has approved daprodustat (Jesduvroq, GSK ...
Renal & Urology News2y
FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs. The FDA has approved daprodustat, the first oral treatment for anemia for adults ...
FiercePharma2y
As GSK gears up for high-stakes daprodustat panel review, FDA flags some safety concerns
The trials compared the drug with approved erythropoiesis-stimulating agents (ESAs). In the trials, daprodustat increased hemoglobin levels to a "similar extent” as the approved ESAs.
McKnight's Long-Term Care News2y
FDA approves first oral anemia drug for renal patients on dialysis
The Food and Drug Administration has approved Jesduvroq tablets (daprodustat), the first oral treatment for renal disease-related anemia in adults who have been on dialysis for four months or more ...
Yahoo Finance2y
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
GSK PLCGSK announced that the FDA approved its daprodustat drug, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), treatment of anemia due to chronic kidney disease (CKD ...
pharmaphorum2y
GSK's daprodustat will have to face FDA advisory committee
GSK has said that its daprodustat for anaemia associated ... clinical trial to bolster the data for the drug, although it was subsequently approved in the EU. Meanwhile, it concluded vadadustat ...
Healio2y
FDA review committee recommends daprodustat for patients on dialysis
Please provide your email address to receive an email when new articles are posted on . Weighing the potential benefits for two different kidney patient populations, a review board for the FDA ...
FDA to offer faster drug reviews to companies promoting ‘national priorities’
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...
London South East2y
Daprodustat approved by US FDA for anaemia of CKD | Regulatory News - London South East
Jesduvroq is the only oral HIF-PHI approved in the US ... Phase III trials to assess the efficacy and safety profile of daprodustat for the treatment of anaemia of CKD across the disease spectrum.
Monthly Prescribing Reference2y
Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...